On February 25, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Acelyrin
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
Mirum Pharmaceuticals Inc (MIRM) announced on [date of press release] that the U.S. Food and Drug Administration (FDA) has approved CTEXLIâ„¢ (chenodiol) tablet
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLIâ„¢ (chenodiol) tablets, a bile
On February 18, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 5,298,328 shares of Acelyrin Inc. This acqu
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
On February 7, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring 4,210,525 shares of Galapagos NV. This acqu
On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 12,642,279 shares of Mirum Pha
On December 31, 2024, Eventide Asset Management, LLC executed a significant transaction involving Mirum Pharmaceuticals Inc. The firm reduced its holdings by se
/PRNewswire-PRWeb/ -- Genomenon, Inc., a leading provider of genomic intelligence solutions, has announced a strategic partnership with Mirum Pharmaceuticals,...
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platfo
Mirum Pharmaceuticals Inc (MIRM), a biopharmaceutical company focused on treating rare diseases, announced on January 10, 2025, that its Compensation Committee